Skip to content
Screener

Palvella Therapeutics PVLA Enterprise value

Enterprise value at other companies

Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$3.99B+717%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$1.98B+79.5%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$1.82B+17.9%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$3.36B+92.5%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$703.89M+36.7%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$684.98M+89.8%

Other financials

Income statement

See full
Revenue$53.0K-97.3%
Operating income-$14.9M-88.7%
Net income-$15.8M-92.6%
EPS (diluted)-$1.20-62.2%

Balance sheet

See full
Cash & equivalents$206.4M+173%
Total debt$584.0K—
Total equity$232.3M+318%
Total assets$263.8M+232%

Cash flow

See full
Operating cash flow-$10.9M-60.5%
CapEx--100%
Free cash flow-$2.7M+72.0%

Valuation

See full
Market cap$2.23B+417%

Profitability

See full
Operating margin-183.2%—
Net margin71.7%+40.4pp
FCF margin-99.8%-34.2pp

Returns & leverage

See full
Return on equity-34.2%—
Debt / equity0×—
Current ratio28.9×+20.0×

Where this comes from

Calculated from Palvella Therapeutics’s reported figures.

$1.8Bmarket cap+$584.0Ktotal debt−$206.4Mcash and equivalents=$1.58B

The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026. Open the filing →

Filed
May 7, 2026, 8:30 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-210463

FAQ

What is Palvella Therapeutics's enterprise value?
Palvella Therapeutics (PVLA) reported enterprise value of $1.58B in Q1 2026.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.

Ask your AI about Palvella Therapeutics's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude